Barbara Pro

Lymphoma Doc @columbiacancer @nyphospital Tweets are my own

[Barbara Pro @bpromd]

Some personal news….after 6 great years @LurieCancer I joined @columbiacancer as director of the lymphoma program. I am thrilled to be working with an exceptional group of clinical reasearchers and scientists to advance the understanding and treatment of lymphoma.
#lymsm

[The Viny Lab @cohesinlab]

Transcription factors don’t fail in MDS—they’re misdirected.

Today in Blood, we show how loss of STAG2 rewires chromatin accessibility to redirect GATA1 and alter blood cell fate.

https://t.co/zlpMlz1St3

[Toby Eyre @tobyeyre82]

Duvelisib Induces Deep Responses in PTCL: Final Results of the Phase 2 PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma | Journal of Clinical Oncology https://t.co/utzDvdDSrs

[Herbert Irving Comprehensive Cancer Center @columbiacancer]

As more people live longer during and after cancer, doctors are turning their attention to the heart. ❤️‍🩹
@ColumbiaMed cardio-oncologist Dr. Jayant K. Raikhelkar discusses the growing field helping manage long-term heart effects of cancer treatments. https://t.co/5woMl3XE2N

[Jennifer Amengual @jenamengual]

Excited to publish our work in @Bloodneoplasia @BloodPortfolio @ASH_hematology. https://t.co/jFPJVNLxp7
Congrats to our PTLD Working Group for all their contributions! @ev_lando @patrickwgould @hjcherng #curelymphoma @columbiacancer @ColumbiaMed

[Blood Journals Portfolio @BloodPortfolio]

We're delighted to welcome Dr. Jennifer Amengual as a new Associate Editor for Blood Neoplasia! Dr. Amengual is an Associate Professor of Medicine at @columbiamed and a physician-scientist whose research focuses on developing targeted therapies for patients with lymphoma.

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #SOHO2025 | PRESENTATION
Suzanne Lentzsch @SLentzsch @columbiacancer discussed novel approaches and therapies for the treatment of #amyloidosis. A dFLC <10mg/L is associated with the best outcomes, SoC therapy is Dara-VCd for all patients, and venetoclax for patients with t(11;14). Future directions may include BCMA-directed ADCs, BiTEs, and CAR T.
Follow our live feed for more updates: https://t.co/JmRGgBYAtN
#myeloma #mmsm #MultipleMyeloma

[DAVA Oncology @DAVAOnc]

ILC is biologically distinct yet often treated like IBC-NST. Dr. Massimo Cristofanilli (@WeillCornell) shows genomic/transcriptomic profiling reveals enrichment in actionable mutations (PIK3CA, ERBB2) &amp; unique PAM50 subtypes #DAVABreast

[Barbara Pro @bpromd]

👏👏👏@SedaToluMD @columbiacancer

[DAVA Oncology @DAVAOnc]

Dr. Seda Tolu @Columbia presented the combination of JAK inhibitor Ruxolitinib and ICI Pembrolizumab for treating 9p-amplified lymphomas. The regimen enhances apoptosis and T-cell infiltration, while reducing MDSCs and MYC expression in 9p⁺ lymphomagenesis. #DAVAHeme

[PER @gotoPER]

The Big Apple brought big insights this weekend at #MXH25 🍎🩸 The energy was electric, the debates were sharp, and the NYC vibes were unmatched.
See you next year for more insights and more Medical Crossfire. 🔥 https://t.co/4Hn67EMMuT #gotoPER

@Dr_AmerZeidan @szusmani @bpromd

[Barbara Pro @bpromd]

Up next 💥Should we treat smoldering myeloma now? Yes or not ? 💥with @DrOlaLandgren and @SLentzsch chaired by @szusmani

[Barbara Pro @bpromd]

Great discussion 👏on #MDS at Medical Crossfire 💥with @Dr_AmerZeidan @yasminabaza1 &amp; Dr @Ramikomrokji #MXH25

[Barbara Pro @bpromd]

@Dr_AmerZeidan Ty! Big thanks to Drs Lamanna &amp; Jean-Louis @ @columbiacancer &amp; @DanilovLab for an excellent discussion!

[Michael Hughes @MSHughes_MD]

Results from 4 pivotal phase 3 trials (MIDAS, PERSEUS, IsKIA, ADVANCE) representing current thinking on the role of ASCT in NDMM, masterfully summarized and contextualized by @SLentzsch! #ASCO25 #MYELOMA #MRD @columbiacancer

[Gareth Morgan @DrGarethMorgan1]

Suzanne Lentzsch receives the CoMy award for women’s achievement in MM very deserved and supported by her family and work colleagues

[Barbara Pro @bpromd]

Goals of CML frontline therapy @DrHKantarjian #ThinkTank2025

[PER @gotoPER]

🗽 Big debates. Bold insights. Live in New York.
Join us for the 9th Annual #MXH25 — a one-day, fast-paced event where experts tackle today’s most pressing challenges in hematologic cancer.

HCPs save 75% with code MXH75: https://t.co/gc6kqyFJEH

@bpromd @szusmani @Dr_AmerZeidan https://t.co/vZoxzWPvuA

[PER @gotoPER]

Start spreadin’ the news… we’re headed to New York for the 9th Annual Live Medical Crossfire®: Hematologic Malignancies!
Join @bpromd @szusmani @Dr_AmerZeidan for expert-led debates and real-time insights!
🗽Get 75% off HCP registration with code MXH75 https://t.co/gc6kqyFJEH

[Barbara Pro @bpromd]

Sunday 🦅 mood 🏈
#GoBirds

[Barbara Pro @bpromd]

@jaehyukchoimd @utswnews Congratulations Jae!

[Barbara Pro @bpromd]

Combination JAK inhibition and Immune checkpoint blockade being presented by @SedaToluMD 👏 @columbiacancer #ASH2024 #ASH24